Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)

Claire Roddie; Jae H Park; Eleni Tholouli; Karamjeet Sandhu; Paul Shaughnessy; Pere Barba; Manuel Guerreiro; Deborah Yallop; Aaron Logan; Mehrdad Abedi; Pierre Lao-Sirieix; Ping Wang; Wolfram Brugger; Bijal D Shah; Michael R Bishop; Daniel J DeAngelo; Elias Jabbour

doi:10.1016/j.jtct.2025.12.050

February 1, 2026Transplantation and Cellular Therapy

Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)

View at Publisher

Ask AI

Bookmark

Share

Key Points

Persistence of CAR T-cells at month 3 correlates with better clinical outcomes.
The study found that higher T-cell persistence is linked to improved response rates.
Assessment of T-cell persistence was crucial for evaluating the therapy's effectiveness.
These findings support the need for monitoring T-cell levels post-treatment for optimal management.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis shows T-cell persistence at month 3 predicts clinical outcomes in adults with R/R B-ALL, highlighting its importance for therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roddie et al. (2026) studied this question.

synapsesocial.com/papers/69a76060c6e9836116a2d0d3 https://doi.org/10.1016/j.jtct.2025.12.050

View at Publisher

Ask AI

Bookmark

Share

Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading